Skip to main content
Top
Published in: Tumor Biology 5/2016

01-05-2016 | Original Article

Anticancer function of α-solanine in lung adenocarcinoma cells by inducing microRNA-138 expression

Authors: Furui Zhang, Rui Yang, Guojun Zhang, Ruirui Cheng, Yong Bai, Huasi Zhao, Xinhua Lu, Hui Li, Shanshan Chen, Juan Li, Shujun Wu, Ping Li, Xiaonan Chen, Qianqian Sun, Guoqiang Zhao

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

Currently, lung cancer is still a main cause of malignancy-associated death worldwide. Even though various methods for prevention and treatment of lung cancer have been improved in recent decades, the 5-year survival rate has remained very low. Insights into the anticancer function of small-molecule anticancer compounds have opened our visual field about cancer therapy. α-Solanine has been well studied for its antitumor properties, but its effect in lung cancer and associated molecular mechanisms have not yet been evaluated. To explore the anticancer function of α-solanine, we performed an MTT assay, Transwell arrays, colony-forming survival assay, quantitative reverse transcription PCR (qRT-PCR), Western blotting, and dual luciferase reporter assays in A549 and H1299 cells. We found that α-solanine not only inhibited cell migration and invasion ability but also enhanced the chemosensitivity and radiosensitivity of A549 and H1299 cells. Moreover, we discovered that α-solanine could affect the expression of miR-138 and focal adhesion kinase (FAK), both of which were also found to affect the chemosensitivity and radiosensitivity of A549 and H1299 cells. In conclusion, α-solanine could affect miR-138 and FAK expression to restrict cell migration and invasion and enhance the chemosensitivity and radiosensitivity of A549 and H1299 cells. The α-solanine/miR-138/FAK cascade can probably be a potential therapy target against lung adenocarcinoma.
Literature
2.
go back to reference Genestreti G, Di Battista M, Cavallo G, Bartolotti M, Brandes AA. Maintenance therapy in non-small cell lung cancer. Expert Rev Anticancer Ther. 2015;15:839–46.CrossRefPubMed Genestreti G, Di Battista M, Cavallo G, Bartolotti M, Brandes AA. Maintenance therapy in non-small cell lung cancer. Expert Rev Anticancer Ther. 2015;15:839–46.CrossRefPubMed
3.
go back to reference Crvenkova S, Pesevska M. Important prognostic factors for the long-term survival in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy. J BUON. 2015;20:775–81.PubMed Crvenkova S, Pesevska M. Important prognostic factors for the long-term survival in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy. J BUON. 2015;20:775–81.PubMed
4.
go back to reference Jabbour SK, Kim S, Haider SA, Xu X, Wu A, Surakanti S, et al. Reduction in tumor volume by cone beam computed tomography predicts overall survival in non-small cell lung cancer treated with chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2015;92:627–33.CrossRefPubMed Jabbour SK, Kim S, Haider SA, Xu X, Wu A, Surakanti S, et al. Reduction in tumor volume by cone beam computed tomography predicts overall survival in non-small cell lung cancer treated with chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2015;92:627–33.CrossRefPubMed
5.
go back to reference Hata A, Katakami N, Tanaka K, Takeshita J, Matsumoto T, Monden K, et al. Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer. Anticancer Res. 2014;34:275–81.PubMed Hata A, Katakami N, Tanaka K, Takeshita J, Matsumoto T, Monden K, et al. Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer. Anticancer Res. 2014;34:275–81.PubMed
6.
go back to reference Köhler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie. 2013;36:510–8.CrossRefPubMed Köhler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie. 2013;36:510–8.CrossRefPubMed
7.
go back to reference Sgambato A, Casaluce F, Maione P, Rossi A, Ciardiello F, Gridelli C. Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown? J Thorac Dis. 2014;6:578–80.PubMedPubMedCentral Sgambato A, Casaluce F, Maione P, Rossi A, Ciardiello F, Gridelli C. Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown? J Thorac Dis. 2014;6:578–80.PubMedPubMedCentral
8.
go back to reference Gong T, Wang CF, Yuan JR, Li Y, Gu JF, Zhao BJ, et al. Inhibition of tumor growth and immunomodulatory effects of flavonoids and scutebarbatines of Scutellaria barbata D. Don in Lewis-Bearing C57BL/6 Mice. Evid Based Complement Alternat Med. 2015;2015:630760.PubMedPubMedCentral Gong T, Wang CF, Yuan JR, Li Y, Gu JF, Zhao BJ, et al. Inhibition of tumor growth and immunomodulatory effects of flavonoids and scutebarbatines of Scutellaria barbata D. Don in Lewis-Bearing C57BL/6 Mice. Evid Based Complement Alternat Med. 2015;2015:630760.PubMedPubMedCentral
9.
go back to reference Wang L, Feng J, Chen X, Guo W, Du Y, Wang Y, et al. Myricetin enhance chemosensitivity of 5-fluorouracil on esophageal carcinoma in vitro and in vivo. Cancer Cell Int. 2014;14:71.CrossRefPubMedPubMedCentral Wang L, Feng J, Chen X, Guo W, Du Y, Wang Y, et al. Myricetin enhance chemosensitivity of 5-fluorouracil on esophageal carcinoma in vitro and in vivo. Cancer Cell Int. 2014;14:71.CrossRefPubMedPubMedCentral
10.
go back to reference Zang W, Wang T, Wang Y, Li M, Xuan X, Ma Y, et al. Myricetin exerts anti-proliferative, anti-invasive, and pro-apoptotic effects on esophageal carcinoma EC9706 and KYSE30 cells via RSK2. Tumour Biol. 2014;35:12583–92.CrossRefPubMed Zang W, Wang T, Wang Y, Li M, Xuan X, Ma Y, et al. Myricetin exerts anti-proliferative, anti-invasive, and pro-apoptotic effects on esophageal carcinoma EC9706 and KYSE30 cells via RSK2. Tumour Biol. 2014;35:12583–92.CrossRefPubMed
11.
go back to reference Sun F, Zheng XY, Ye J, Wu TT, Wang J, Chen W. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer. 2012;64:599–606.CrossRefPubMed Sun F, Zheng XY, Ye J, Wu TT, Wang J, Chen W. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer. 2012;64:599–606.CrossRefPubMed
12.
go back to reference Weng CJ, Yen GC. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer Metastasis Rev. 2012;31:323–51.CrossRefPubMed Weng CJ, Yen GC. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer Metastasis Rev. 2012;31:323–51.CrossRefPubMed
13.
go back to reference Punjabi S, Cook LJ, Kersey P, Marks R, Cerio R. Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicenter study. Int J Dermatol. 2008;47:78–82.CrossRefPubMed Punjabi S, Cook LJ, Kersey P, Marks R, Cerio R. Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicenter study. Int J Dermatol. 2008;47:78–82.CrossRefPubMed
14.
go back to reference Friedman M, Lee KR, Kim HJ, Lee IS, Kozukue N. Anticarcinogenic effects of glycoalkaloids from potatoes against human cervical, liver, lymphoma, and stomach cancer cells. J Agric Food Chem. 2005;53:6162–9.CrossRefPubMed Friedman M, Lee KR, Kim HJ, Lee IS, Kozukue N. Anticarcinogenic effects of glycoalkaloids from potatoes against human cervical, liver, lymphoma, and stomach cancer cells. J Agric Food Chem. 2005;53:6162–9.CrossRefPubMed
15.
go back to reference Lee KR, Kozukue N, Han JS, Park JH, Chang EY, Baek EJ, et al. Glycoalkaloids and metabolites inhibit the growth of human colon (HT29) and liver (HepG2) cancer cells. J Agric Food Chem. 2004;52:2832–9.CrossRefPubMed Lee KR, Kozukue N, Han JS, Park JH, Chang EY, Baek EJ, et al. Glycoalkaloids and metabolites inhibit the growth of human colon (HT29) and liver (HepG2) cancer cells. J Agric Food Chem. 2004;52:2832–9.CrossRefPubMed
16.
go back to reference Lv C, Kong H, Dong G, Liu L, Tong K, Sun H, et al. Antitumor efficacy of α-solanine against pancreatic cancer in vitro and in vivo. PLoS One. 2014;9:e87868.CrossRefPubMedPubMedCentral Lv C, Kong H, Dong G, Liu L, Tong K, Sun H, et al. Antitumor efficacy of α-solanine against pancreatic cancer in vitro and in vivo. PLoS One. 2014;9:e87868.CrossRefPubMedPubMedCentral
17.
go back to reference Lu MK, Shih YW, Chang Chien TT, Fang LH, Huang HC, Chen PS. α-Solanine inhibits human melanoma cell migration and invasion by reducing matrix metalloproteinase-2/9 activities. Biol Pharm Bull. 2010;33:1685–91.CrossRefPubMed Lu MK, Shih YW, Chang Chien TT, Fang LH, Huang HC, Chen PS. α-Solanine inhibits human melanoma cell migration and invasion by reducing matrix metalloproteinase-2/9 activities. Biol Pharm Bull. 2010;33:1685–91.CrossRefPubMed
18.
go back to reference Mohsenikia M, Alizadeh AM, Khodayari S, Khodayari H, Kouhpayeh SA, Karimi A, et al. The protective and therapeutic effects of alpha-solanine on mice breast cancer. Eur J Pharmacol. 2013;718:1–9.CrossRefPubMed Mohsenikia M, Alizadeh AM, Khodayari S, Khodayari H, Kouhpayeh SA, Karimi A, et al. The protective and therapeutic effects of alpha-solanine on mice breast cancer. Eur J Pharmacol. 2013;718:1–9.CrossRefPubMed
19.
go back to reference Li J, Li P, Chen T, Gao G, Chen X, Du Y, et al. Expression of microRNA-96 and its potential functions by targeting FOXO3 in non-small cell lung cancer. Tumour Biol. 2015;36:685–92.CrossRefPubMed Li J, Li P, Chen T, Gao G, Chen X, Du Y, et al. Expression of microRNA-96 and its potential functions by targeting FOXO3 in non-small cell lung cancer. Tumour Biol. 2015;36:685–92.CrossRefPubMed
20.
go back to reference Wang Y, Zang W, Du Y, Ma Y, Li M, Li P, et al. Mir-655 up-regulation suppresses cell invasion by targeting pituitary tumor-transforming gene-1 in esophageal squamous cell carcinoma. J Transl Med. 2013;11:301.CrossRefPubMedPubMedCentral Wang Y, Zang W, Du Y, Ma Y, Li M, Li P, et al. Mir-655 up-regulation suppresses cell invasion by targeting pituitary tumor-transforming gene-1 in esophageal squamous cell carcinoma. J Transl Med. 2013;11:301.CrossRefPubMedPubMedCentral
21.
go back to reference Amankwatia EB, Chakravarty P, Carey FA, Weidlich S, Steele RJ, Munro AJ, et al. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. Br J Cancer. 2015;112:1480–90.CrossRefPubMedPubMedCentral Amankwatia EB, Chakravarty P, Carey FA, Weidlich S, Steele RJ, Munro AJ, et al. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. Br J Cancer. 2015;112:1480–90.CrossRefPubMedPubMedCentral
22.
go back to reference Asuthkar S, Velpula KK, Chetty C, Gorantla B, Rao JS. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget. 2012;3:1439–54.CrossRefPubMedPubMedCentral Asuthkar S, Velpula KK, Chetty C, Gorantla B, Rao JS. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget. 2012;3:1439–54.CrossRefPubMedPubMedCentral
23.
go back to reference Yang H, Tang Y, Guo W, Du Y, Wang Y, Li P, et al. Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells. Tumour Biol. 2014;35:6557–65.CrossRefPubMed Yang H, Tang Y, Guo W, Du Y, Wang Y, Li P, et al. Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells. Tumour Biol. 2014;35:6557–65.CrossRefPubMed
24.
go back to reference Hasanain M, Bhattacharjee A, Pandey P, Ashraf R, Singh N, Sharma S, et al. α-Solanine induces ROS-mediated autophagy through activation of endoplasmic reticulum stress and inhibition of Akt/mTOR pathway. Cell Death Dis. 2015;6:e1860.CrossRefPubMedPubMedCentral Hasanain M, Bhattacharjee A, Pandey P, Ashraf R, Singh N, Sharma S, et al. α-Solanine induces ROS-mediated autophagy through activation of endoplasmic reticulum stress and inhibition of Akt/mTOR pathway. Cell Death Dis. 2015;6:e1860.CrossRefPubMedPubMedCentral
25.
go back to reference Health Quality Ontario. Epidermal growth factor receptor mutation (EGFR) testing for prediction of response to EGFR-targeting tyrosine kinase inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10:1–48. Health Quality Ontario. Epidermal growth factor receptor mutation (EGFR) testing for prediction of response to EGFR-targeting tyrosine kinase inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10:1–48.
26.
go back to reference Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer. 2010;67:257–74.CrossRefPubMed Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer. 2010;67:257–74.CrossRefPubMed
27.
go back to reference Wang JQ, Wang T, Shi F, Yang YY, Su J, Chai YL, et al. A randomized controlled trial comparing clinical outcomes and Toxicity of lobaplatin- versus cisplatin-based concurrent chemotherapy plus radiotherapy and high-dose-rate brachytherapy for FIGO stage II and III cervical cancer. Asian Pac J Cancer Prev. 2015;16:5957–61.CrossRefPubMed Wang JQ, Wang T, Shi F, Yang YY, Su J, Chai YL, et al. A randomized controlled trial comparing clinical outcomes and Toxicity of lobaplatin- versus cisplatin-based concurrent chemotherapy plus radiotherapy and high-dose-rate brachytherapy for FIGO stage II and III cervical cancer. Asian Pac J Cancer Prev. 2015;16:5957–61.CrossRefPubMed
28.
go back to reference Naka A, Takeda R, Shintani M, Ogane N, Kameda Y, Aoyama T, et al. Organic cation transporter 2 for predicting cisplatin-based neoadjuvant chemotherapy response in gastric cancer. Am J Cancer Res. 2015;5:2285–93.PubMedPubMedCentral Naka A, Takeda R, Shintani M, Ogane N, Kameda Y, Aoyama T, et al. Organic cation transporter 2 for predicting cisplatin-based neoadjuvant chemotherapy response in gastric cancer. Am J Cancer Res. 2015;5:2285–93.PubMedPubMedCentral
29.
go back to reference MacDonagh L, Gray SG, Finn SP, Cuffe S, O’Byrne KJ, Barr MP. The emerging role of microRNAs in resistance to lung cancer treatments. Cancer Treat Rev. 2015;41:160–9.CrossRefPubMed MacDonagh L, Gray SG, Finn SP, Cuffe S, O’Byrne KJ, Barr MP. The emerging role of microRNAs in resistance to lung cancer treatments. Cancer Treat Rev. 2015;41:160–9.CrossRefPubMed
30.
go back to reference Zhou L, Qiu T, Xu J, Wang T, Wang J, Zhou X, et al. miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res. 2013;19:677–83.CrossRefPubMed Zhou L, Qiu T, Xu J, Wang T, Wang J, Zhou X, et al. miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res. 2013;19:677–83.CrossRefPubMed
31.
go back to reference Qiu T, Zhou L, Wang T, Xu J, Wang J, Chen W, et al. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Int J Mol Med. 2013;32:593–8.PubMed Qiu T, Zhou L, Wang T, Xu J, Wang J, Chen W, et al. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Int J Mol Med. 2013;32:593–8.PubMed
32.
go back to reference Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun. 2003;311:786–92.CrossRefPubMed Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun. 2003;311:786–92.CrossRefPubMed
33.
go back to reference Smith CS, Golubovskaya VM, Peck E, Xu LH, Monia BP, Yang X, et al. Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res. 2005;15:357–62.CrossRefPubMed Smith CS, Golubovskaya VM, Peck E, Xu LH, Monia BP, Yang X, et al. Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res. 2005;15:357–62.CrossRefPubMed
Metadata
Title
Anticancer function of α-solanine in lung adenocarcinoma cells by inducing microRNA-138 expression
Authors
Furui Zhang
Rui Yang
Guojun Zhang
Ruirui Cheng
Yong Bai
Huasi Zhao
Xinhua Lu
Hui Li
Shanshan Chen
Juan Li
Shujun Wu
Ping Li
Xiaonan Chen
Qianqian Sun
Guoqiang Zhao
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4528-2

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine